Interview with Karl Nikitsch, Menarini Austria
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
Address: ‘EURO PLAZA Gebäude G, 5. Stock, Am Euro Platz 2 A-1120 Wien’,Austria
Tel: + 43 (0) 1/260 44-0
Web: http://www.msd.at/
IN 36 YEARS TO THE TOP
MSD has been in Austria for 36 years now. Accelerating the pace of innovation in research and development of innovative drugs is one of the most important tasks of MSD. We are investing large sums in competent staff and clinical research.
MSD Austria has 200 employees and reported 2009 sales of 156.3 million euros.
The guarantee of a reliable partnership with physicians and patients is one of the fundamental principles of MSD. MSD is committed to the company and all stakeholders in health care to be a competent, reliable and trustworthy partner.
Our employees act exactly in this sense: responsibly, with integrity and ethically.
As a research-based pharmaceutical company focused on developing innovative MSD patented medicines. The research focus is on the application areas of asthma and allergic rhinitis, cardiovascular disease and lipid metabolism, HIV, infection, endocrinology, Diabetiologie, oncology, and eye diseases.
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
Can you give our readers a snapshot of Austroplant’s scope of activities and its structure in Austria and the central European market? Austroplant/Dr Peithner belongs to the Schwabe Group, the…
Dr Prchla, you have been heading Merck’s Austrian subsidiary over the past eighteen months. What do you see as the key strengths of your company today? Mirroring the company’s structure,…
Just like other European countries, Austria is in the search for meaningful savings in healthcare. Austria’s increasingly price sensitive pharma market is seeing the rise of generic medicines gaining market…
Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so…
You have been General Secretary of PHARMIG since 2004 and have witnessed the market’s development over the past 8 years. What have been the most important changes since you started…
See our Cookie Privacy Policy Here
